HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Unpublished And Under Review? US FDA’s CBD Policy Draft Guidance Still Has Industry Talking

Executive Summary

Supplements containing hemp-derived cannabidiols aren’t typical products subject to FDA’s regulatory oversight, and the document stating its thinking on enforcement in the market submitted to the Office of Management and Budget isn’t a typical draft guidance.

You may also be interested in...



US FDA On Effects From Cannabinoids Potentially Differing By Gender: Stay Tuned

"The use of these products during pregnancy and lactation raises additional questions and concerns,” says Kaveeta Vasisht, FDA Office of Women’s Health director. "There is a great deal that we simply do not yet know about CBD and beyond CBD, even more that we do not know about the other compounds found in hemp," said Douglas Throckmorton, Center for Drug Evaluation and Research deputy director. 

Senate Appropriators Ask USDA To Remove Business ‘Roadblocks’ In Hemp Production Rule

Senate committee “is concerned” USDA's interim final rule “creates roadblocks for farmers” by imposing short timeframes for testing harvested hemp for levels of THC  in crops and requiring testing only by DEA-registered labs.

Herbalife Adds Cannabinoid Skin Care Line On Top Of Reporting Record Quarterly Results

Direct seller announces both its third-quarter results and launch of Enrichual Hemp Relief Balm and Facial Serum formulated with broad-spectrum cannabinoids. Its $1.5bn net sales were led by 55.1% growth in the US and Canada to $398.7m.

Related Content

Topics

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel